SBRT Plus Lenvatinib and TACE for Advanced Primary HCC: A Phase 3 Trial (SEARCH)
Status:
Not yet recruiting
Trial end date:
2027-02-01
Target enrollment:
Participant gender:
Summary
This is a phase 3, multicentri, randomised, open label study. The purpose is to investigate
the safety and efficacy of stereotactic body radiation therapy (SBRT) combined with
transarterial chemoembolization (TACE) and lenvatinib (LEN) in the treatment of advanced
hepatocellular carcinoma with portal vein tumor thrombus.